- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- The Academy
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Big Data In Healthcare
- Institutional Planning and Policy
- Master of Medical Sciences In Clinical Investigation
- Office of Global Education
- Portugal Clinical Scholars Research Training Program
- Safety Quality Informatics and Leadership
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Human Resources
- Jobs @ HMS
- Dental Medicine
- Harvard University
- Contact us
Harvard Medical School researchers at Boston Children’s Hospital have reprogrammed mature blood cells from mice into blood-forming hematopoietic stem cells (HSCs), using a cocktail of eight genetic switches called transcription factors. The reprogrammed cells, which the researchers have dubbed “induced HSCs,” or iHSCs, have the functional hallmarks of HSCs, are able to self-renew like HSCs and can give rise to all of the cellular components of blood like HSCs.
The findings mark a significant step toward one of the most sought-after goals of regenerative medicine: the ability to produce HSCs suitable for hematopoietic stem cell transplantation from other cell types, particularly from more mature or differentiated cells.
The research team, led by Derrick J. Rossi, assistant professor of stem cell and regenerative biology at Harvard Medical School and the Faculty of Arts and Sciences, reported its work online April 24 in the journal Cell.
HSCs are the basic starting material for HSC transplants, regardless of their source (bone marrow, umbilical cord blood, peripheral blood). The success of any individual patient’s HSC transplant is tied to the number of HSCs available for transplant: the more cells, the more likely the transplant will take hold. However, HSCs are quite rare.
HSCs account for only about one in every 20,000 cells in the bone marrow, said Rossi, who is also an HMS assistant professor of pediatrics at Boston Children’s. “If we could generate autologous HSCs from a patient’s other cells, it could be transformative for transplant medicine and for our ability to model diseases of blood development.”
In their study, Rossi and his collaborators, including Jonah Riddell, lead author of the paper and a postdoctoral researcher in Rossi’s lab, screened gene expression in 40 different types of blood and blood progenitor cells from mice. From this screen they identified 36 transcription factors—genes that control when other genes are turned on and off—that are expressed exclusively in HSCs, not in cells that arise from them.
“Blood cell production invariably goes in one direction: from stem cells, to progenitors, to mature effector cells,” Rossi explained. “We wanted to reverse the process and derive HSCs from differentiated blood cells using transcription factors that we found were specific to HSCs.”
In a series of mouse transplantation experiments, Rossi’s team found that six—Hlf, Runx1t1, Pbx1, Lmo2, Zfp37 and Prdm5—of the 36 factors, plus two additional factors not originally identified in their screen—Mycn and Meis1—were sufficient to robustly reprogram two kinds of blood progenitor cells (pro-/pre-B cells and common myeloid progenitor cells) into iHSCs.
Rossi’s team reprogrammed their source cells by exposing them to viruses containing the genes for all eight factors and a molecular switch that turned the factor genes on in the presence of doxycycline. They then transplanted the exposed cells into recipient mice and activated the genes by giving the mice doxycycline.
The resulting iHSCs were capable of generating the entire blood cell repertoire in the transplanted mice, showing that they had gained the ability to differentiate into all blood lineages. Stem cells collected from those recipients were themselves capable of reconstituting the blood of secondary transplant recipients, proving that the eight-factor cocktail could instill the capacity for self-renewal—a hallmark property of HSCs.
Taking the work a step further, Rossi’s team treated mature mouse myeloid cells with the same eight-factor cocktail. Again, when transplanted into mice, iHSCs were generated that produced all of the blood lineages and could regenerate the blood of secondary transplant recipients.
Stuart Orkin, the HMS David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute and a co-author on the paper, noted that the use of mice as a kind of reactor for reprogramming marks a novel direction in HSC research.
“In the blood research field, no one has the conditions to expand HSCs in the tissue culture dish,” said Orkin, who is also one of the leaders of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. “Instead, by letting the reprogramming occur in mice, Rossi takes advantage of the signaling and environmental cues HSCs would normally experience.”
Orkin added that iHSCs are nearly indistinguishable from normal HSCs at the transcriptional level. “The iHSCs have a gene expression pattern remarkably similar to HSCs.”
The current findings are far from translation to the transplantation clinic. Still to be answered are the precise contribution of each of the eight factors to the reprogramming process and whether approaches that do not rely on viruses and transcription factors can have similar success. It also is not yet known whether the same results can be achieved using human cells or whether other, non-blood cells can be reprogrammed to iHSCs.
But with these results Rossi’s team has already succeeded where many other attempts have failed. And iHSCs in their current state constitute a promising springboard for better understanding of HSC biology and development.
“Our data show that the functional and molecular identity of HSCs can be tapped with relatively few factors using the paradigm of cellular reprogramming in a manner similar to the generation of induced pluripotent stem cells,” Rossi said.
The study was supported by the National Heart, Lung, and Blood Institute (grant numbers R01HL107630 and U01HL100001), the National Institute on Aging (grant number R00AG029760), the National Institute of Diabetes and Digestive and Kidney Diseases (grant number U01DK072473-01), GlaxoSmithKline, the Leona M. and Harry B. Helmsley Charitable Trust, the New York Stem Cell Foundation and the Harvard Stem Cell Institute. Orkin is an investigator with the Howard Hughes Medical Institute.
Adapted from a Boston Children’s news release.